|Elizabeth J. Davis, MD|
Nashville, TN, USA
Note: this page contains regimens specific to angiosarcoma.
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) PubMed
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
All lines of therapy
|Study||Dates of enrollment||Evidence|
|Agulnik et al. 2012 (NU 04S1)||2005-08 to 2011-04||Phase 2|
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
- NU 04S1: Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. Epub 2012 Aug 21. link to original article contains dosing details in manuscript PubMed NCT00288015
|Penel et al. 2008 (ANGIOTAX)||Phase 2|
- Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
- Dexamethasone (Decadron) 8 mg IV once per day on days 1, 8, 15, prior to paclitaxel
- Cimetidine (Tagamet) 200 mg IV once per day on days 1, 8, 15, prior to paclitaxel
- Dexchlorpheniramine (Polaramine) 5 mg IV once per day on days 1, 8, 15, prior to paclitaxel
- "Standard antiemetics (mainly Metoclopramide (Reglan)) were prescribed as clinically indicated by the treating physician"
28-day cycle for 6 cycles
- ANGIOTAX: Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. link to original article contains dosing details in manuscript PubMed
|Study||Dates of enrollment||Evidence||Comparator||Comparative Efficacy|
|Jones et al. 2022 (TAPPAS)||2017-2019||Phase 3 (C)||Pazopanib & Carotuximab||Did not meet primary endpoint of PFS|
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
- Pazopanib (Votrient) 800 mg PO once per day
- TAPPAS: Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. link to original article link to PMC article contains dosing details in manuscript PubMed NCT02979899